Literature DB >> 7199463

Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds.

N Brock, J Pohl, J Stekar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7199463

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


× No keyword cloud information.
  17 in total

1.  The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.

Authors:  L D Lewis; D L Fitzgerald; P Mohan; N Thatcher; P G Harper; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

2.  Mesna or cysteine prevents chloroacetaldehyde-induced cell death of human proximal tubule cells.

Authors:  Gerald Schwerdt; Antje Kirchhoff; Ruth Freudinger; Brigitte Wollny; Andreas Benesic; Michael Gekle
Journal:  Pediatr Nephrol       Date:  2007-02-02       Impact factor: 3.714

3.  Prevention of cyclophosphamide-induced urotoxicity by reduced glutathione and its effect on acute toxicity and antitumor activity of the alkylating agent.

Authors:  O Tofanetti; E Cavalletti; A Besati; G Pratesi; G Pezzoni; F Zunino
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Ifosfamide combination chemotherapy in advanced breast cancer.

Authors:  H Schmid; M Kaufmann; E M Grischke; G Bastert
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders.

Authors:  M Fukuoka; S Negoro; N Masuda; K Furuse; M Kawahara; N Kodama; H Ikegami; S Nakamura; H Nishio; T Ohnoshi
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

6.  Ifosfamide chemotherapy for pancreatic carcinoma.

Authors:  L H Einhorn; P J Loehrer
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics.

Authors:  N Brock
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

8.  L-cysteine prodrug protects against cyclophosphamide urotoxicity without compromising therapeutic activity.

Authors:  J C Roberts; D J Francetic; R T Zera
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors.

Authors:  N C Munshi; P J Loehrer; S D Williams; C Langefeld; G Sledge; C R Nichols; B J Roth; A Neuman; W B Walsh; L H Einhorn
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

10.  Does 2-mercaptoethane sulphonate (mesna) prevent cyclophosphamide and azathioprine induced immunosuppression? In vitro studies.

Authors:  S A Al-Safi; J L Maddocks
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.